Humanigen announced first patient dosed in NIH ACTIV-5/Big Effect trial evaluating Lenzilumabル for COVID-19
On Oct. 29, 2020, Humanigen announced that the first patient had been dosed at the Emory University School…
On Oct. 29, 2020, Humanigen announced that the first patient had been dosed at the Emory University School…
On Oct. 29, 2020, PerkinElmer announced that the FDA had issued Emergency Use Authorization (EUA) to allow sample…
On Oct. 29, 2020, Takeda Pharmaceutical announced that it would import and distribute 50 million doses of Moderna’s…
On Oct. 29, 2020, Emulate announced that it had entered into a Cooperative Research and Development Agreement (CRADA)…
On Oct. 28, 2020, Novartis and Molecular Partners announced an option and license agreement to develop, manufacture and…
On Oct. 28, 2020, CVS Health announced plans to expand COVID-19 testing services currently offered at select CVS…
On Oct. 28, 2020, researchers at the NIH announced that they had discovered a biological pathway that the…
On Oct. 28, 2020, Eli Lilly announced the New England Journal of Medicine had published data from the…
On Oct. 28, 2020, Eli Lilly announced an initial agreement with the U.S. government to supply 300,000 vials…
On Oct. 28, 2020, Regeneron announced positive, prospective results from an ongoing Phase 2/3 seamless trial in the…
On Oct. 27, 2020, Novavax announced updates on its Phase 3 clinical development program of NVX-CoV2373, its COVID-19…
On Oct. 27, 2020, CHF Solutions announced that it had shipped Aquadexル product to medical facilities in Tennessee…
On Oct. 27, 2020, Aurinia Pharmaceuticals announced the funding and initiation of an open-label exploratory trial evaluating the…
On Oct. 27, 2020, Nektar Therapeutics announced that it has received FDA clearance for an Investigational New Drug…
On Oct. 27, 2020, Moderna announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United…
On Oct. 26, 2020, Todos Medical announced the completion of clinical validation and CLIA certification for MOTO+PARA’s mobile…
On Oct. 26, 2020, the Department of Defense (DOD), in coordination with the Department of Health and Human…
On Aug. 27, 2020, immunologists at Scripps Research, in partnership with colleagues at the IAVI Neutralizing Antibody Center,…
On Oct. 26, 2020, BioSig Technologies and its majority owned subsidiary, ViralClear Pharmaceuticals, announced the halting of its…
On Oct. 26, 2020, Moderna announced a supply agreement with the Ministry of Public Health of Qatar for…
On Oct. 26, 2020, ContraFect announced that it had initiated an expanded access program to provide exebacase for…
On Oct. 26, 2020, Todos Medical announced the completion of the instrument validation in its mobile lab division….
On Oct. 26, 2020, Taconic Biosciences announced immediate humanized ACE2 mouse model availability for COVID-19 research. The SARS-CoV-2…
On Oct. 26, 2020, Membrion announced a breakthrough in the fight against the COVID-19 virus: a molecular coating…
On Oct. 23, 2020, Entos Pharmaceuticals announced it was receiving advisory services and funding of up to $5…
On Oct. 23, 2020, Johnson & Johnson announced that it was preparing to resume recruitment in the pivotal…
On Oct. 22, 2020, Moderna announced that it had completed enrollment of 30,000 participants for the Phase 3…
On Oct. 22, 2020, Todos Medical announced that it had entered into an exclusive supply agreement with U.S….
On Oct. 22, 2020, Gilead Sciences announced that the FDA had approved the antiviral drug Veklury (remdesivir) for…
On Oct. 22, 2020, the FDA approved the antiviral drug Veklury (remdesivir) for use in adult and pediatric…